<unk>  has been used in the past for the following indications: * Recurrent miscarriage in pregnancy * Menopausal hormone therapy for the treatment of menopausal symptoms such as hot flashes and vaginal atrophy * Hormone therapy for hypoestrogenism (e.g., gonadal dysgenesis, premature ovarian failure, and after oophorectomy) * Postpartum lactation suppression to prevent or reverse breast engorgement * Gonorrheal vaginitis (discontinued following the introduction of the antibiotic penicillin) * Prostate cancer and breast cancer * Prevention of tall stature in tall adolescent girls * Treatment of acne in girls and women * As an emergency postcoital contraceptive * As a means of chemical castration for hypersexuality and paraphilias in men and sex offenders * Prevention of the testosterone flare at the start of gonadotropin-releasing hormone agonist (GnRH agonist) therapy * Feminizing hormone therapy for transgender women<unk>  was used at a dosage of 0.2 to 0.5 mg/day in menopausal hormone therapy. Interest in the use of<unk>  to treat prostate cancer in men continues today. However, use of bioidentical parenteral estrogens like polyestradiol phosphate has been advocated in favor of oral synthetic estrogens like<unk>  due to their much lower risk of cardiovascular toxicity. In addition to prostate cancer, some interest in the use of<unk>  to treat breast cancer in women continues today as well. However, similarly to the case of prostate cancer, arguments have been made for the use bioidentical estrogens like estradiol instead of<unk>  for breast cancer. Oral<unk>  at 0.25 to 0.5 mg/day is effective in the treatment of hot flashes in men undergoing androgen deprivation therapy for prostate cancer.
Diethylstilbestrol
Stilbestrol
Polydiethylstilbestrol phosphate
Ethinylestradiol sulfonate
Ethinylestradiol sulfate
Ethinylestradiol
Chloromethylandrostenediol
Estradiol dienantate